ArticleIranian journal of otorhinolaryngology2026
FeNO as a Non-Invasive Biomarker of Type 2 Inflammation in Chronic Rhinosinusitis with Nasal Polyps: Correlation with Serum IgE and Eosinophils.
Article in Iranian journal of otorhinolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic rhinosinusitis with nasal polyps is a heterogeneous inflammatory disorder often driven by type 2 inflammation. Identification of non-invasive biomarkers, such as fractional exhaled nitric oxide (FeNO), may support the assessment and personalized management. Materials and Methods: In this cross-sectional study, 141 patients with clinically and radiologically confirmed CRSwNP were assessed. FeNO levels, nasal eosinophilia, serum IgE, peripheral blood eosinophil counts, and skin prick test results were evaluated. Disease severity was measured using the SNOT-22 and Lund-Mackay CT scores. Results: FeNO showed a significant correlation with nasal eosinophilia (r = 0.53, p < 0.001), a moderate correlation with serum IgE (r = 0.40, p < 0.001), and a weak correlation with blood eosinophils (r = 0.17, p = 0.047). Serum IgE was significantly associated with both SNOT-22 and Lund-Mackay scores. FeNO did not show significant correlation with symptom severity or radiological extent, suggesting its use as a supportive marker rather than a stand-alone predictor. Conclusion: FeNO may serve as a potential non-invasive marker for type 2 inflammation in CRSwNP, though it may not predict disease severity. Combining FeNO with other markers could improve clinical endotyping and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.